Selection processes, streamlined robotics, and immunoglobulin transient expression instrumentation are also part of the agreement.

Bayer HealthCare obtained a nonexclusive research licence for the use of BioInvent International’s n-CoDeR® library for the discovery of human mAbs. BioInvent will also provide an extended antibody technology suite including its selection processes, streamlined robotics, and immunoglobulin transient expression technology.


Bayer HealthCare will fund all activities. BioInvent will receive license fees, milestone payments, and escalating royalties. The agreement allows for up to 14 antibody products to be developed.


The n-CoDeR library contains approximately 2 x 1010 highly diverse fully human antibody fragments, generating antibodies with good affinities and selectivities, according to BioInvent.

Previous articleTPG Biotech to Fund Development of Two Drugs from JCR
Next articleVistaGen Expands Stem Cell Alliance with Canadian Institutes